Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease

Sponsor
University of Illinois at Urbana-Champaign (Other)
Overall Status
Unknown status
CT.gov ID
NCT03221114
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
126
1
2
45
2.8

Study Details

Study Description

Brief Summary

The largest epidemiologic study of Hispanic/Latino participants thus far, i.e., the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) documented that 80% of men and 71% of women have at least one major cardiovascular disease (CVD) risk factor. The American Heart Association emphasizes that current CVD prevention efforts are sparse and ineffectual in minority populations and acknowledges the need for new and more effective disease prevention strategies. This observational study and pilot cluster-randomized clinical trial seeks to implement and evaluate a novel 8-week Positive Psychology (PP) Intervention (compared to an attention control condition) in Hispanic/Latino adults with uncontrolled hypertension, i.e., elevated 24-hour ambulatory blood pressure, with primary interest in testing efficacy for clinically meaningful improvements in cardiovascular function.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Positive Psychological Intervention
N/A

Detailed Description

The study features piloting of a cluster-randomized trial to determine whether a positive psychology (PP) intervention is associated with greater improvements in blood pressure compared to an attention control condition. The pilot trial additionally evaluates the efficacy of the PP intervention with respect to psychological well-being, hypertension-related health behaviors, autonomic cardiac control, and high-sensitivity C-reactive protein. Serum blood assays will facilitate exploration of mechanistic indicators linking psychological well-being to cardiac functioning.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
126 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Cluster-randomized control trialCluster-randomized control trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessors will be blind to intervention assignment and will only collect clinical data at baseline, 8-, and 12-weeks.
Primary Purpose:
Treatment
Official Title:
Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease
Actual Study Start Date :
Oct 1, 2017
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Jul 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Positive Psychological Intervention

Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.

Behavioral: Positive Psychological Intervention
Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
Other Names:
  • Positive Affect Intervention
  • No Intervention: Wait list control

    Receipt after the active treatment group has completed the positive psychological intervention.

    Outcome Measures

    Primary Outcome Measures

    1. Change from Baseline Ambulatory Blood Pressure at 8- and 12-weeks [Baseline, 8-, and 12-weeks]

      The device, Vitavue, consists of a wireless microcontroller that connects to a desktop computer running proprietary software when operated in real time connected mode. Alternatively, it can be operated in standalone unconnected mode by logging acquired data to an internal memory storage device. The device contains a number of sensors including ECG single channel amplifier, Multispectral Photodiode to record photo pulse plethysmograms, temperature sensor to measure skin temperature, and an accelerometer to record the level of activity.

    Secondary Outcome Measures

    1. Center for Epidemiological Studies Depression Scale (CESD): Change from Baseline Depressive Symptoms at 8- and 12-weeks [Baseline, 8-, and 12-weeks]

      Center for Epidemiological Studies Depression-Scale

    2. Life Orientation Test-Revised (LOT-R): Change from Baseline Dispositional Optimism at 8- and 12-weeks [Baseline, 8-, and 12-weeks]

      Life Orientation Test-Revised

    3. General Well-being Schedule: Change in Baseline Emotional Vitality at 8- and 12-weeks [Baseline, 8-, and 12-weeks]

      General Well-being Schedule

    4. Life Engagement Test (LET): Change in Baseline Life engagement and Meaning at 8- and 12-weeks [Baseline, 8-, and 12-weeks]

      Life Engagement Test

    Other Outcome Measures

    1. Physical Activity: Change in Hypertension-related Health Behavior(s) [Baseline, 8-, and 12-weeks]

      Physical Activity using Fitbit One

    2. Diet: Change in Hypertension-related Health Behavior(s) [Baseline, 8-, and 12-weeks]

      Diet using Scored Sodium Questionnaire

    3. Change in Heart Rate Variability [Baseline, 8-, and 12-weeks]

      Beat-to-beat interval

    4. Change in High-sensitivity C-Reactive Protein [Baseline, 8-, and 12-weeks]

      mg/L

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Hispanics/Latinos recruited from Catholic church sites in Chicago-land area

    • aged ≥18

    • fluent in English or Spanish with ≥8th grade education

    • elevated 24-hour ambulatory blood pressure levels (systolic BP> 140 mmHg and >90 mmHg for diastolic BP).

    Exclusion Criteria:
    • Unavailable for study period; have cognitive impairment denoting dementia

    • have severely reduced life expectancy

    • are currently enrolled in psychotherapy or take prescribed antidepressants

    • history or current diagnosis of bipolar disorder, dissociative disorder, psychosis, or substance abuse

    • have severe depression.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St. Pius V Parish Chicago Illinois United States 60608

    Sponsors and Collaborators

    • University of Illinois at Urbana-Champaign
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Illinois at Urbana-Champaign
    ClinicalTrials.gov Identifier:
    NCT03221114
    Other Study ID Numbers:
    • 1K01HL130712-01A1
    First Posted:
    Jul 18, 2017
    Last Update Posted:
    Mar 20, 2019
    Last Verified:
    Mar 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Illinois at Urbana-Champaign
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 20, 2019